2021 San Antonio Breast Cancer Symposium Coverage

Every December, the San Antonio Breast Cancer Symposium brings together clinicians, researchers, and advocates to discuss the latest breast cancer study results. We’re proud to present our coverage below.

Study Compares Aromatase Inhibitors vs. Tamoxifen for Pre-Menopausal Women With Early-Stage, Hormone Receptor-Positive Breast Cancer

Black Women More Likely To Develop Lymphedema After Breast Cancer Treatment Than White Women

Experimental Elacestrant Shows Promise for Pre-Treated Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer

Top Research Presented at the 2021 San Antonio Breast Cancer Symposium, with Sara Tolaney, MD, MPH

Aromatase Inhibitors versus Tamoxifen for Pre-Menopausal Women Diagnosed With Early-Stage, Hormone Receptor-Positive Disease, with Jeremy Braybrooke, BSc, BM, FRCP, PhD, and Rosie Bradley, MSc, BSc

Experimental Elacestrant: A Standard of Care for Pre-Treated, Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer?, with Aditya Bardia, MD, MPH

 

This content made possible by Lilly Oncology.